



DOTTIKON ES Proposes Share Split and Authorized Capital Increase for Growth

Dottikon, Switzerland, October 20, 2020 – DOTTIKON ES Group, positioned as strategic development and manufacturing partner and specialized in the area of hazardous reactions and the exclusive synthesis of active pharmaceutical ingredients (API) and fine chemicals, will propose a share split and an authorized capital increase to support its growth at an Extraordinary General Meeting.

With countries striving to reduce their geopolitical dependence and the respective ties of interest, the expansion of the tripolar world order, and increasing regionalization, the trend to repatriate chemical production continues. As a result, DOTTIKON ES expects ongoing strong demand for chemical process development and production capacities, not least from the rapidly growing and innovative biotech and pharmaceutical market. The planning for additional chemical production capacities within DOTTIKON ES is well advanced. In particular, DOTTIKON ES is about to launch the realization phase for a new chemical multipurpose API production plant to support long-term growth. In addition, the planning phase for further new pilot and API drying capacities was initiated. In order to secure the financing of these capacity expansion steps, the Board of Directors of DOTTIKON ES HOLDING AG intends to create options and room for maneuver. The Board of Directors of DOTTIKON ES HOLDING AG has therefore decided to convene an Extraordinary General Meeting on November 27, 2020. The following amendments to the by-laws will be proposed to the General Meeting

- Share split in the ratio of 1:10 (from nominal value CHF 0.10 to CHF 0.01)
- Building additional options to support growth by authorizing the Board of Directors to issue new registered shares using authorized share capital of up to ten percent of the current share capital

DOTTIKON ES closed its first business half-year 2020/21 on September 30, 2020. The respective results and the Half-Year Report 2020/21 will be published as planned on November 27, 2020. For the ongoing full business year 2020/21, DOTTIKON ES continues to expect net sales above the previous year's figure.

DOTTIKON ES manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. Its safety culture created over the past 105 years guides the innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing in order to challenge, tighten, or shorten conventional chemical synthesis routes, improve selectivities, yields, and purities, and reduce waste. The versatile technology and equipment portfolio is used, maintained, and continuously expanded to design, develop, and optimize chemical processes and technical manufacturing procedures for the rapid scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.



dottikon

DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development as well as clear and transparent data and process documentation and customer communication.

DOTTIKON ES HOLDING AG is listed on the SIX Swiss Exchange.

Symbol: DESN

Security number: 2073900

ISIN: CH0020739006

For further information please contact

Markus Blocher, Ph.D.

CEO

Dottikon ES Holding AG

Tel +41 56 616 82 01

Fax +41 56 616 89 45

investor-relations@dottikon.com